Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 19th July 2022

2. Minutes and Summary Notes from last meeting

On account of the Trust response to the Covid-19 Pandemic, this meeting was held via Teams.
The minutes and summary notes of the Medicines Group Meeting held on 25th April 2022 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

a) Formulary Applications

Full Applications

- **Declaration of conflicts of interest by Group members**

Declaration of any conflicts of interest by any Group members - Nil

- **Formulary applications**

Full Applications

Nil

Ex-panel

- **Benilexa® One Handed 20 micrograms/24 hours (Levonorgestrel 52mg) Intrauterine Delivery System**

Request from GUM for Benilexa One Handed 20 micrograms/24 hours (Levonorgestrel 52mg) Intrauterine Delivery System to be added to the formulary in place of Levosert®
(Levonorgestrel 52mg).
The current pricing of Benilexa is £71 per unit compared to the current formulary alternative of Levosert® at £66. The two products may be deemed equivalent in their pharmaceutical constituent and device dimensions. The purported advantage of Benilexa® over Levosert® is the one-handed applicator and insertion technique (compared with the two handed insertion technique used with Levosert®). At present nurses and clinicians at times report difficulty inserting Levosert® which results in the discarding of the device.
Outcome: Levonorgestrel monograph will be updated on the formulary as a generic product. Pharmacy to procure products depending on availability. Relevant PGD to be updated accordingly.

Removals

- **Nil**

NICE Approved drug applications

- **Sotorasib 120mg Tablets in line with TA781**

TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
Outcome: Approved for addition to the formulary in line with NICE TA781

- **Tucatinib 50mg and 150mg Tablets (Tukysa®) in line with TA786**

TA786 - Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
Outcome: Added to the formulary in line with NICE TA786

- **Tepotinib 225mg Tablets in line with NICE TA789**

TA789 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations
Outcome: Added to the formulary in line with NICE TA789

- **Romosozumab 105 mg solution for injection in pre-filled pen in line with NICE TA791**

TA790 Romosozumab for treating severe osteoporosis
Outcome: Added to the formulary in line with NICE TA791

- **Diroximel Fumarate 231mg Capsules (Vumerity®) in line with NICE TA794**

TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis
Outcome: Added to the formulary in line with NICE TA794

Pharmacoeconomic Board requests

- **Ustekinumab second IV initial dose**

Approved by PEB on 05/05/22 - For noting
Outcome: Noted

- **Tocilizumab for Anti-GAD antibody syndrome with Opsoclonus Myoclonus Syndrome**

Approved by the Pharmacoeconomic Board on 31/05/2022 - For noting
Outcome: Noted

- **Tocilizumab for Castleman's Disease**

Approved by PEB on 22/06/22 - For noting
Outcome: Noted

- **Ustekinumab for Crohn's Disease**

Approved by PEB on 27/06/22 - For noting
Outcome: Noted

FOC Schemes

- **Abemaciclib (Verzenios®) for Breast Cancer**

FOC Scheme involving the use of Abemaciclib in the management of Breast Cancer
Outcome: Scheme approved for use within the Trust

- **Bulevirtide (Hepcludex®) for Hepatitis Delta**

FOC Scheme involving the use of Bulevirtide for the management of Hepatitis Delta
Outcome: Scheme approved for use within the Trust

Other

- **Baracitinib for Covid-19**

The Recovery Trial demonstrates that Baricitinib reduces the risk of death when given to hospitalised patients with severe COVID-19. Between February and December 2021
The benefit of baricitinib was consistent regardless of which other COVID-19 treatments the patients were also receiving, including corticosteroids, tocilizumab, or remdesivir.
Patients hospitalised due to COVID-19 are eligible for treatment with baricitinib under the published UK clinical access policy (available here) if the specific criteria is met.
Baricitinib can be considered in children (age 2 to 17 years inclusive) with severe COVID-19, guided by clinical judgement and multi-disciplinary team assessment.
Outcome: Approved for the management of Covid-19

- **UMP Form - Imvanex**

UMP form for use of Imvanex in the Trust for Monkeypox vaccination
Outcome: Noted as a UMP in use in the Trust

- **UMP Form - Tecovirimat**

UMP form for use of Tecovirimat in the Trust for the treatment of Monkeypox
Outcome: Noted as a UMP in use in the Trust

4.2 Trust Medicines Policy

- **TMP Section 17. Injectable Medicines Policy**

Routine review and update
- Section added re. storage requirement for flushes
- Section added re. flushing of IV giving sets

Outcome: Approved

4.3 Medicines Optimisation

- **Trust COVID-19 Anti-infective Guidelines**

Trust Guideline on the management of Covid-19. Approved by the Anti-microbial Steering Group and usually ratified by Covid Gold. Request made for this updated guideline (Version 13) to be ratified by Trust Medicines Group.
Latest updates:
- Inclusion of Baracitinib for severe refractory Covid-19
- Update to the definition of patients at high-risk of complication for Covid-19
- CMDU triage pathway has been updated accordingly.

Outcome: Noted

- **Re-audit of Pharmacy unlicensed medicinal product stock holding and storage at Chelsea and Westminster Hospital and West Middlesex University Hospital Sites**

This re-audit (undertaken in May 2022) provides assurance of the ongoing governance and stock management of unlicensed medicines within the pharmacy departments at Chelsea and Westminster Hospital (CW) and West Middlesex University Hospital (WM) Sites.
Outcome: Noted

4.4 NICE Technical Appraisals and Guidance

a) NICE Technology Appraisals published in March to May 2022

3 TA appraisals published in March 2022

TA780 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (24/03/2022)
Formulary status / Action
Both included on formulary
Numbers likely to treat:
CWH - 1-2 patients per year
WMUH - N/A

TA781 - Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (30/03/2022)
Formulary status / Action
Action: Add Sotorasib to the formulary following receipt of an application form from the Oncology Team
Included in Section 4.1

TA782 - Agraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (Terminated appraisal) (30/03/2022)
Formulary status / Action
Nil - Terminated Appraisal

5 TA appraisals published in April 2022

TA783 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (13/04/2022)
Formulary status / Action
Included on formulary
Numbers likely to treat:
CWH - 10-15 patients per year
WMUH - 5-10 patients per year

TA784 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (20/04/2022)
Formulary status / Action
Not included on formulary
CWH - N/A
WMUH - N/A

TA785 - Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (Terminated appraisal) (20/04/2022)
Formulary status / Action
Nil - Terminated Appraisal

TA786 - Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies (27/04/2022)
Formulary status / Action
Tucatinib not include on formulary
Trastuzumab and capecitabine included on formulary
Action: Add Tucatinib to the formulary following receipt of an application form from the Oncology Team
Included in Section 4.1

TA787 - Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (27/04/2022)
Formulary status / Action
Both included on the formulary
Numbers likely to treat:
WMUH: 0
CWH: 5-10 patients per year

4 TA appraisals published in May 2022

TA788 Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (11/05/2022)
Formulary status / Action
Included on the formulary
Numbers likely to treat:
WMUH: 0

CWH: 1 patient per year

TA789 Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (15/05/2022)
Formulary status / Action
Not included on formulary
Action: Add Tepotinib to the formulary following receipt of an application form from the Oncology Team
Included in Section 4.1

TA790 TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (Terminate appraisal)
Formulary status / Action
Nil - Terminated Appraisal

TA791 Romosozumab for treating severe osteoporosis (25/05/2022
Formulary status / Action
Action: Add to the formulary following a completed application from the Rheumatology Team - Included in Section 4.1

TA792 Filgotinib for treating moderately to severely active ulcerative colitis (01/06/2022)
Formulary status / Action
Included on the formulary
Numbers likely to treat
20 patients across both sites.

TA793 Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (Terminated appraisal)
Formulary status / Action
Nil - Terminated Appraisal

TA794 Diroximel fumarate for treating relapsing–remitting multiple sclerosis (08/06/2022)
Formulary status / Action
Action - Add to the formulary following a completed application from the Neurology Team - Included in Section 4.1

TA795 Ibrutinib for treating Waldenstrom's macroglobulinaemia (Not recommended)
Formulary status / Action
Nil - Not recommended

TA796 Venetoclax for treating chronic lymphocytic leukaemia (105/06/2022)
Included on the formulary
Numbers likely to treat:
WMUH: 0
CWH: 5 patients per year

TA797 Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (Terminated appraisal)
Formulary status / Action
Nil - Terminated Appraisal

TA798 Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (22/06/2022)
Formulary status / Action
Nil - Not recommended

TA799 Faricimab for treating diabetic macular oedema (29/06/2022)
Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Ophthalmology Team

TA800 Faricimab for treating wet age-related macular degeneration (26/06/2022)
Formulary status / Action
Not included on the formulary
Action: Add to the formulary following receipt of an application form from the Ophthalmology Team

TA801 Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (26/06/2022)
Formulary status / Action
Included on the formulary
Numbers likely to treat:
CWH: 0
WMUH: 10-15 Patients per year

TA802 Cemiplimab for treating advanced cutaneous squamous cell carcinoma (29/06/2022)
Formulary status / Action
Included on the formulary
Numbers likely to treat:
CWH: 2
WMUH: 0

b) NICE Highly Specialised Technology Appraisals published since last meeting

2 HST appraisals published in March 2022

HST18 - Atidarsagene autotemcel for treating metachromatic leukodystrophy (28/03/2022)
Formulary status / Action
Action: Nil - CWFT is not a commissioned site for treating under this NICE HST

HST19 - Elosulfase alfa for treating mucopolysaccharidosis type 4A
Formulary status / Action
Action: Nil - CWFT is not a commissioned site for treating under this NICE HST

4.5 IVIG requests

- **IVIG Issues for March 2022 - CW Site**

There were 12 IVIG issues in March 2022, with 7 new requests
Outcome: Noted

- **IVIG Issues for March 2022 - WMUH Site**

There were 7 IVIG issues in March 2022, with 3 new requests
Outcome: Noted

- **IVIG issues for April 2022- CWH Site**

There were 12 IVIG issues in April 2022, with 8 new requests
Outcome: Noted

- **IVIG issues for April 2022- WMUH Site**

There were 15 IVIG issues in April 2022, with 10 new requests
Outcome: Noted

- **IVIG issues for May 2022- CWH Site**

There were 14 IVIG issues in May 2022, with 8 new requests
Outcome: Noted

- **IVIG issues for May 2022- WMUH Site**

There were 13 IVIG issues in May 2022, with 3 new requests
Outcome: Noted

4.6 Items for noting

- **Quarterly Controlled Drug Summary Report - Q4 2021/22**

Quarterly Controlled Drug Summary Report for Q4 2021/22
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q3 2021/22**

Quarterly CD Accountable Officer Report for Q4 2021/22
Outcome: Noted

- **Medication Safety Bulletin - Controlled Drug Incidents 21-22**

Medication Safety Bulletin relating to Controlled Drug Incidents 21-22
Outcome: Noted

- **Medication Safety Bulletin: Lessons learned from a serious incident - Methyprednisolone**

Medication Safety Bulletin relating to Lessons learned: Methylprednisolone
Outcome: Noted

- **MHRA Drug Safety Update - April 2022**

MHRA update for April 2022
Outcome: Noted

- **MHRA Drug Safety Update - May 2022**

MHRA update for May 2022
Outcome: Noted

- **MHRA Drug Safety Update - June 2022**

MHRA update for June 2022
Outcome: Noted

4.7 Meeting minutes for noting

- **NWLIF NDP Meeting minutes - May 2022**

Minutes from NWLIF NDP Meeting held May 2022
Outcome: Noted

- **Medication Safety Group meeting minutes - May 2022**

Minutes from Medical Safety Group meeting held May 2022
Outcome: Noted

- **Antimicrobial Stewardship Group meeting minutes - May 2022**

Minutes from Antimicrobial Stewardship Group meeting held May 2022
Outcome: Noted

5. Any other business

Proposal to move to Unlicensed Diamorphine Pre-Filled Syringes for Spinal Anaesthesia in Maternity

A proposal was presented to source and supply unlicensed Diamorphine 500mcg in 0.5ml prefilled syringes (PFS) for intrathecal administration, while the licensed ampoules (5mg/10mg) are still in circulation and available intermittently but not reliably. DHSC issued a Supply Disruption Alert (SDA) in March 2020, which remains in place currently.

This unlicensed product is made by the manufacturing unit at Royal Liverpool and Broadgreen Hospital. It comes as a 500micorgrams in 0.5ml prefilled syringe and is stored in a locked fridge. The product packaging, which clearly denotes that it is intended for intrathecal injection, with a yellow label highlighting this and there is also a tamper evident closure.

There has been a recent patient safety incident at WM Hospital where an inappropriate dose of preservative free morphine was given intrathecally, so Pharmacy wish to procure this product to mitigate the risk.
Outcome: Approved

6. Date of next meeting

Next meeting

- **21st November 2022**
- **30th January 2023**

Time: 8am-9am
Location: via Teams